Literature DB >> 33408716

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.

Wei Li1, Anghui Peng2, Huajun Wu1, Yingyao Quan2,3, Yong Li2, Ligong Lu2, Min Cui1.   

Abstract

Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.
Copyright © 2020 Li, Peng, Wu, Quan, Li, Lu and Cui.

Entities:  

Keywords:  immunotherapy; nanomedicine; nanotherapy; review; tumor

Mesh:

Substances:

Year:  2020        PMID: 33408716      PMCID: PMC7779686          DOI: 10.3389/fimmu.2020.601497

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  135 in total

1.  Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy.

Authors:  Xiaojing Shi; Qinqin Cheng; Tianling Hou; Menglu Han; Goar Smbatyan; Julie E Lang; Alan L Epstein; Heinz-Josef Lenz; Yong Zhang
Journal:  Mol Ther       Date:  2019-11-27       Impact factor: 11.454

Review 2.  Management of toxicities of immune checkpoint inhibitors.

Authors:  Lavinia Spain; Stefan Diem; James Larkin
Journal:  Cancer Treat Rev       Date:  2016-02-06       Impact factor: 12.111

3.  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Authors:  Paolo Antonio Ascierto; Pier Francesco Ferrucci; Antoni Ribas; Rosalie Fisher; Michele Del Vecchio; Victoria Atkinson; Henrik Schmidt; Jacob Schachter; Paola Queirolo; Georgina V Long; Anna Maria Di Giacomo; Inge Marie Svane; Michal Lotem; Gil Bar-Sela; Felix Couture; Bijoyesh Mookerjee; Razi Ghori; Nageatte Ibrahim; Blanca Homet Moreno
Journal:  Nat Med       Date:  2019-06-06       Impact factor: 53.440

4.  Dopamine Delivery via pH-Sensitive Nanoparticles for Tumor Blood Vessel Normalization and an Improved Effect of Cancer Chemotherapeutic Drugs.

Authors:  Mohammad Taleb; Yanping Ding; Bin Wang; Na Yang; Xuexiang Han; Chong Du; Yingqiu Qi; Yinlong Zhang; Zeinab Farhadi Sabet; Hamideh Rezvani Alanagh; Ayeesha Mujeeb; Khosro Khajeh; Guangjun Nie
Journal:  Adv Healthc Mater       Date:  2019-08-05       Impact factor: 9.933

5.  Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.

Authors:  Sin-Tzu Ning; Shin-Yu Lee; Ming-Feng Wei; Cheng-Liang Peng; Susan Yun-Fan Lin; Ming-Hsien Tsai; Pei-Chi Lee; Ying-Hsia Shih; Chun-Yen Lin; Tsai-Yueh Luo; Ming-Jium Shieh
Journal:  ACS Appl Mater Interfaces       Date:  2016-07-06       Impact factor: 9.229

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

8.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.

Authors:  Wantong Song; Limei Shen; Ying Wang; Qi Liu; Tyler J Goodwin; Jingjing Li; Olekasandra Dorosheva; Tianzhou Liu; Rihe Liu; Leaf Huang
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

Review 9.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Authors:  S K Daniel; K M Sullivan; K P Labadie; V G Pillarisetty
Journal:  Clin Transl Med       Date:  2019-04-01

Review 10.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

View more
  4 in total

1.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04

Review 2.  Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors:  Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal:  Bioact Mater       Date:  2021-03-18

Review 3.  Strategies for Remodeling the Tumor Microenvironment Using Active Ingredients of Ginseng-A Promising Approach for Cancer Therapy.

Authors:  Mo Li; Xin Wang; Ying Wang; Shunchao Bao; Qing Chang; Linlin Liu; Shuai Zhang; Liwei Sun
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

4.  Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.

Authors:  Pengkai Wu; Haitian Zhang; Yin Yin; Meiling Sun; Shuai Mao; Huihui Chen; Yexuan Deng; Shuai Chen; Shuo Li; Beicheng Sun
Journal:  Adv Sci (Weinh)       Date:  2022-03-25       Impact factor: 17.521

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.